Thera-SAbDab

SPARTALIZUMAB

>   Structural Summary
TherapeuticSpartalizumab
TargetPDCD1
Heavy ChainEVQLVQSGAEVKKPGESLRISCKGSGYTFTTYWMHWVRQATGQGLEWMGNIYPGTGGSNFDEKFKNRVTITADKSTSTAYMELSSLRSEDTAVYYCTRWTTGTGAYWGQGTTVTVSS
Light ChainEIVLTQSPATLSLSPGERATLSCKSSQSLLDSGNQKNFLTWYQQKPGQAPRLLIYWASTRESGVPSRFSGSGSGTDFTFTISSLEAEDAATYYCQNDYSYPYTFGQGTKVEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG4
Highest Clinical Trial (August '23)Phase-II
Estimated Status (August '23)Active
Recorded Developmental Technologyna
INN Year Proposed2017
INN Year Recommended2018
Companies InvolvedAsan Medical Center, Dana-Farber Cancer Institute, Novartis, Novartis Oncology, Palobiofarma, Seoul National University Hospital
Conditions Approvedna
Conditions ActiveMalignant melanoma, Breast cancer, Colorectal cancer, Diffuse large B cell lymphoma, Gastric cancer, Nasopharyngeal cancer, Non-small cell lung cancer, Solid tumours, Acute myeloid leukaemia, Cancer, Liver cancer, Lymphoma, Multiple myeloma, Myelodysplastic syndromes, Ovarian cancer, Pancreatic cancer, Renal cancer
Conditions DiscontinuedNeuroendocrine tumours
Notes

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]

Our privacy policy